Structure Therapeutics CSO sells 7,878 ADS

Structure Therapeutics Inc.’s Chief Scientific Officer, Xichen Lin, reported an exercise-and-sale transaction involving American Depositary Shares (ADS) tied to the company’s Ordinary Shares.

Rhea-AI Filing Summary

Structure Therapeutics Inc.’s Chief Scientific Officer, Xichen Lin, reported an exercise-and-sale transaction involving American Depositary Shares (ADS) tied to the company’s Ordinary Shares.

Lin exercised share options for 23,634 Ordinary Shares at $0.34 per share, which were converted into 7,878 ADS and then sold at $49.0792 per ADS under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Lin holds 228,960 Ordinary Shares directly and retains share options covering 190,166 additional Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 7,878 shares

Net Sell 5 txns

Insider Lin Xichen

Role CHIEF SCIENTIFIC OFFICER

Sold 7,878 shs ($387K)

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy)	23,634	$0.00	$0.00
Conversion	American Depositary Shares	7,878	$0.00	$0.00
Sale	American Depositary Shares	7,878	$49.0792	$387K
Exercise	Ordinary Shares	23,634	$0.34	$8K
Conversion	Ordinary Shares	23,634	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 190,166 contracts (Direct); American Depositary Shares — 0 contracts (Direct); Ordinary Shares — 228,960 shares (Direct)

Footnotes (8)

1. F1. Reflects price per share in Ordinary Shares.
2. F2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
3. F3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
4. F4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 23,634 Ordinary Shares.
5. F5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
6. F6. 23,634 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 7,878 American Depositary Shares.
7. F7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
8. F8. Reflects price per share in American Depositary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 08:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Xichen

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/25/2026		M		23,634	A	$0.34(1)	252,594	D
Ordinary Shares	06/25/2026		C		23,634(2)	D	$0	228,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$0.34(1)	06/25/2026		M			23,634	(3)	09/10/2029	Ordinary Shares	23,634	$0	190,166(4)	D
American Depositary Shares	(5)	06/25/2026		C		7,878(6)		(5)	(5)	Ordinary Shares	23,634	$0	7,878	D
American Depositary Shares	(5)	06/25/2026		S(7)			7,878	(5)	(5)	Ordinary Shares	23,634	$49.0792(8)	0	D

Explanation of Responses:

1. Reflects price per share in Ordinary Shares.

2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.

3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 23,634 Ordinary Shares.

5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.

6. 23,634 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 7,878 American Depositary Shares.

7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.

8. Reflects price per share in American Depositary Shares.

	/s/ Jun Yoon, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)